Neurotrophic keratitis (NK) is a rare, degenerative corneal disease characterized by reduced or complete loss of corneal sensation, leading to impaired wound healing and corneal damage. NK often arises from conditions such as herpes simplex or zoster infections, diabetes, or surgical damage to the trigeminal nerve. 

NK is classified into stages ranging from epithelial defects to ulceration and perforation of the cornea, which, if left untreated, can lead to vision loss. Growth factors play a critical role in the treatment of NK by promoting nerve regeneration and corneal healing. These biologically active proteins stimulate cell proliferation, repair damaged nerves, and restore the structural and functional integrity of the cornea, offering a targeted therapeutic approach for this challenging condition. ECI’s biologically-derived growth factor formulation helps address NK patients’ unmet needs.

Dry eye disease (DED) symptoms, such as dryness, burning, itching, and redness, can significantly affect a person’s quality of life, making it difficult to perform everyday activities, such as reading, using a computer, or driving. In some cases, DED can also lead to complications, such as corneal abrasions or infections, which can cause further discomfort and vision problems. The chronic nature of DED can even lead to feelings of frustration, anxiety, and depression.